KALA BIO, Inc. Files 8-K on Shareholder Nominations
Ticker: KALA · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1479419
Sentiment: neutral
Topics: corporate-governance, shareholder-activism, filing
Related Tickers: KALA
TL;DR
KALA BIO filed an 8-K about shareholder nominations - board shakeup incoming?
AI Summary
KALA BIO, Inc. filed an 8-K on September 18, 2025, reporting events as of September 16, 2025. The filing pertains to Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 and Other Events. The company, formerly known as Kala Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Arlington, MA.
Why It Matters
This 8-K filing indicates potential changes or discussions regarding board composition and shareholder engagement, which could impact the company's strategic direction.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations and potential board changes can introduce uncertainty and signal activist investor interest, which may affect stock price volatility.
Key Players & Entities
- KALA BIO, Inc. (company) — Registrant
- Kala Pharmaceuticals, Inc. (company) — Former company name
- September 16, 2025 (date) — Earliest event date
- September 18, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Arlington, MA (location) — Principal executive offices
FAQ
What specific shareholder nominations are being reported in this 8-K filing?
The filing indicates 'Shareholder Nominations Pursuant to Exchange Act Rule 14a-11' as an item of disclosure, but the specific names of the nominees are not detailed in the provided text.
What is the significance of 'Other Events' being reported?
The 'Other Events' section is a catch-all for material events that the company deems important to disclose but do not fit into other specific 8-K item categories.
When was KALA BIO, Inc. formerly known as Kala Pharmaceuticals, Inc.?
The company changed its name from Kala Pharmaceuticals, Inc. on December 23, 2009.
What is the principal business address of KALA BIO, Inc.?
The principal executive offices are located at 1167 Massachusetts Avenue, Arlington, MA 02476.
What is the filing date of this 8-K report?
This Form 8-K was filed as of September 18, 2025.
Filing Stats: 784 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2025-09-18 16:24:44
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share KALA The Nasdaq C
Filing Documents
- tm2526405d1_8k.htm (8-K) — 25KB
- 0001104659-25-091272.txt ( ) — 185KB
- kala-20250916.xsd (EX-101.SCH) — 3KB
- kala-20250916_lab.xml (EX-101.LAB) — 33KB
- kala-20250916_pre.xml (EX-101.PRE) — 22KB
- tm2526405d1_8k_htm.xml (XML) — 3KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations . To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
01 Other Events
Item 8.01 Other Events. On September 16, 2025, the Board of Directors of KALA BIO, Inc. (the "Company") established December 11, 2025 as the date of the Company's 2025 annual meeting of stockholders (the "2025 Annual Meeting"). The Company plans to publish additional details regarding the exact time, location and matters to be voted on at the 2025 Annual Meeting in the Company's proxy statement for the 2025 Annual Meeting. Because the date of the 2025 Annual Meeting will change by more than 30 calendar days from the anniversary date of the Company's 2024 annual meeting of stockholders, the Company has set a deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended ("Rule 14a-8") for inclusion in the Company's proxy materials relating to the 2025 Annual Meeting. In order for a proposal under Rule 14a-8 to be timely, it must be received by the Company's Secretary at the principal executive offices of the Company by October 1, 2025, which the Company has determined to be a reasonable time before the Company's proxy materials are due to be printed and sent. Such proposals must also comply with the Company's Third Amended and Restated By-Laws (the "By-Laws") and the rules of the Securities and Exchange Commission regarding the inclusion of stockholder proposals in proxy materials, and any such proposal may be omitted if not in compliance with applicable requirements. The address of the Company's principal executive offices is 1167 Massachusetts Avenue, Arlington, Massachusetts 02476. Stockholders wishing to nominate a director or propose matters to be considered at the 2025 Annual Meeting in the manner contemplated by the By-Laws must submit timely notice to the Company in order for such matters to be considered at the 2025 Annual Meeting. Because the date of the 2025 Annual Meeting will be delayed by more than 60 days from the first anniversary of the Company's 2024 annual meeting of sto
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: September 18, 2025 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary